The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

August 24, 2022

Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.

August 23, 2022

The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.

August 19, 2022

Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.

August 15, 2022

Eric Jonasch, MD, discusses the efficacy and safety of belzutifan observed in the LITESPARK-001 trial for patients with advanced clear cell RCC and the next steps for investigating belzutifan in this patient population.

August 15, 2022

Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.

August 11, 2022

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.

August 11, 2022

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

August 11, 2022

Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.

August 11, 2022

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.

August 10, 2022

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.

August 02, 2022

Poziotinib produced an encouraging overall response rate in patients with non–small cell lung cancer harboring EGFR exon 20 mutations, meeting the primary end point in cohort 1 of a phase 2 trial.

August 02, 2022

The menu of tissue-agnostic oncology drug approvals is growing, generating new treatment options for patients with rare cancers and strengthening the rationale for broad next-generation sequencing.

August 01, 2022

Dr Subbiah discusses research from the 2022 ASCO Annual Meeting, including phase 2 data (NCT04165772) in mismatch repair–deficient, locally advanced rectal cancer; findings from DESTINY-Breast04 (NCT03734029) in HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) in TP53-mutant advanced solid tumors; and data from LIBRETTO-001 (NCT03157128) in RET fusion–positive solid tumors.

July 28, 2022

Ignacio I. Wistuba, MD, explains how major pathological response and pathological complete response should be interpreted and their role as clinical end points.

July 27, 2022

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

July 21, 2022

Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with BRAF V600E–mutant metastatic or unresectable solid tumors and contextualizes the pivotal data for rare tumor types.

July 21, 2022

CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma, according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH.

July 21, 2022

Immune checkpoint inhibitor therapy in relapsed follicular lymphoma can induce immune-related adverse events which can be difficult to diagnose and manage.

July 15, 2022

Major pathological response and recurrence-free survival rates were improved in women vs men with melanoma who received BRAF/MEK inhibitor therapy in the neoadjuvant setting.

July 08, 2022

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.